Advertisement

Complications of Sclerotherapy

  • Girish S. Munavalli
  • Robert A. Weiss

Abstract

Sclerotherapy is the systematic, targeted elimination of intracutaneous and subcutaneous varicose, reticular telangiectasias by the injection of a locally irritating chemical substance, called a sclerosant. Physicians practicing phlebology (the study and science of diagnosis and treatment of veins) rely heavily on the use of sclerotherapy to rid the body of diseased veins. Sclerosants work by direct mechanisms to provoke marked damage of the endothelium of the vessels and possibly transmural wall damage. Subsequently, a local thrombus is generated and, in the long term, damaged veins will be transformed into a fibrous cord, a process referred to as sclerosis. The purpose of sclerotherapy is not just a thrombosis of the vessel, but the definite transformation into a fibrous cord which is impossible to recanalize.1 In essence, the endpoint of this process is functionally analogous to surgical removal of a vein.

Keywords

Hypertonic Saline Varicose Vein Arterial Injection Sodium Tetradecyl Sulfate Cutaneous Necrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Guex JJ, Allaert FA, Gillet JL, et al. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:123–128.PubMedCrossRefGoogle Scholar
  2. 2.
    Goldman MP. Sclerotherapy: treatment of varicose and telangiectatic leg veins. Baltimore: Mosby; 1991.Google Scholar
  3. 3.
    Guex JJ. Contraindications of sclerotherapy, update 2005. J Mal Vasc 2005;30:144–149.PubMedGoogle Scholar
  4. 4.
    Rabe E, Pannier-Fischer F, Gerlach H, et al. Abstract: guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 2004;30:687–693.CrossRefPubMedGoogle Scholar
  5. 5.
    Weiss RA, Feied CF, Weiss MA. Vein diagnosis and treatment: a comprehensive approach. New York: McGraw-Hill; 2001.Google Scholar
  6. 6.
    Goldman MP, Kaplan RP, Duffy DM. Postsclerotherapy hyperpigmentation: a histologic evaluation. J Dermatol Surg Oncol 1987;13:547–550.PubMedGoogle Scholar
  7. 7.
    Georgiev M. Postsclerotherapy hyperpigmentations: a oneyear follow-up. J Dermatol Surg Oncol 1990;16:608–610.PubMedGoogle Scholar
  8. 8.
    Weiss MA, Weiss RA. Efficacy and side effects of 0.1% sodium tetradecyl sulfate in compression sclerotherapy of telangiectasias: comparison to 1% polidocanol and hypertonic saline. J Dermatol Surg Oncol 1991;17:90–91.Google Scholar
  9. 9.
    Tafazzoli A, Rostan EF, Goldman MP. Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation. Dermatol Surg 2000;26:653–656.CrossRefPubMedGoogle Scholar
  10. 10.
    Chatard H. Post-sclerotherapy pigmentation. Phlebol 1976;29:211–216.Google Scholar
  11. 11.
    Duffy DM. Small vessel sclerotherapy: an overview. Adv Dermatol 1988;3:221–242.PubMedGoogle Scholar
  12. 12.
    Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990;16:800–804.PubMedGoogle Scholar
  13. 13.
    Alderman DB. Surgery and sclerotherapy in the treatment of varicose veins. Conn Med 1975;39:467–471.PubMedGoogle Scholar
  14. 14.
    Weiss RA, Weiss MA. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 1990;16:333–336.PubMedGoogle Scholar
  15. 15.
    Bodian EL. Techniques of sclerotherapy for sunburst venous blemishes. J Dermatol Surg Oncol 1985;11:696–704.PubMedGoogle Scholar
  16. 16.
    Alderman DB. Therapy for essential cutaneous telangiectasias. Postgrad Med 1977;61:91–95.PubMedGoogle Scholar
  17. 17.
    Goldman PM. Sclerotherapy for superficial venules and telangiectasias of the lower extremities. Dermatol Clin 1987;5:369–379.CrossRefPubMedGoogle Scholar
  18. 18.
    Tournay PR. Traitment sclerosant des tres fines varicosites intra ou saous dermiques. [Sclerosing treatment of very fine intra or subdermal varicosities]. Soc Fran de Phlebol 1966;19:235–241.Google Scholar
  19. 19.
    Tretbar LL. Spider angiomata: treatment with sclerosant injections. J Kansas Med Soc 1978;79:198–200.PubMedGoogle Scholar
  20. 20.
    Cuttell PJ, Fox JA. The etiology and treatment of varicose pigmentation. Phlebol 1982;35:387–389.Google Scholar
  21. 21.
    Richter GW. The nature of storage iron in idiopathic hemochromatosis and in hemosiderosis. J Exp Med 1960;11:551–569.CrossRefGoogle Scholar
  22. 22.
    Georgiev M. Postsclerotherapy hyperpigmentations. Chromated glycerin as a screen for patients at risk (a retrospective study). J Dermatol Surg Oncol 1993;19:649–652.PubMedGoogle Scholar
  23. 23.
    Thibault PK, Wlodarczyk J. Correlation of serum ferritin levels and postsclerotherapy pigmentation — a prospective study. J Dermatol Surg Oncol 1994;20:684–686.PubMedGoogle Scholar
  24. 24.
    McCoy S, Evans A, Spurrier N. Sclerotherapy for leg telangiectasia — a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg 1999;25:381–385.CrossRefPubMedGoogle Scholar
  25. 25.
    Leach BC, Goldman MP. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatol Surg 2003;29:612–615.CrossRefPubMedGoogle Scholar
  26. 26.
    Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989;20:643–649.CrossRefPubMedGoogle Scholar
  27. 27.
    Weiss RA, Sadick NS, Goldman MP, Weiss MA. Postsclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 1999;25:105–108.CrossRefPubMedGoogle Scholar
  28. 28.
    Duffy DM. Small vessel sclerotherapy: an overview. Adv Dermatol 1988;3:221–242.PubMedGoogle Scholar
  29. 29.
    Duffy DM. Sclerotherapy. In: Alam M, Nguyen TH, eds. Treatment of leg veins. Philadelphia: 2006.Google Scholar
  30. 30.
    Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity, a retrospective analysis. J Dermatol Surg Oncol 1990;16:327–330.PubMedGoogle Scholar
  31. 31.
    Barnhill RL, Wolfe JE Jr. Angiogenesis and the skin. J Am Acad Dermatol 1987;16:1226–1229.CrossRefPubMedGoogle Scholar
  32. 32.
    Bihari I, Magyar E. Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg 2001;27:133–136.CrossRefPubMedGoogle Scholar
  33. 33.
    Shields JL, Jansen GT. Therapy for superficial telangiectasias of the lower extremities. J Dermatol Surg Oncol 1982;8:857–860.PubMedGoogle Scholar
  34. 34.
    Zimmet SE. The prevention of cutaneous necrosis following extravasation of hypertonic saline and sodium tetradecyl sulfate. J Dermatol Surg Oncol 1993;19:641–646.PubMedGoogle Scholar
  35. 35.
    Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April 4–6, 2003, Tegernsee, Germany. Dermatol Surg 2004;30:709–717.CrossRefPubMedGoogle Scholar
  36. 36.
    Forlee MV, Grouden M, Moore DJ, Shanik GD. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006;43:162–164.CrossRefPubMedGoogle Scholar
  37. 37.
    Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003;107:5–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Feied CF, Jackson JJ, Bren TS, et al. Allergic reactions to polidocanol for vein sclerosis. Two case reports. Dermatol Surg Oncol 1994;20:466–468.Google Scholar
  39. 39.
    Bergan J, Pascarella L, Mekenas LJ. Venous disorders: treatment with sclerosant foam. Cardiovasc Surg (Torino) 2006;47:9–18.Google Scholar
  40. 40.
    Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high-concentration sclerotherapy for varicose veins. Dermatol Surg 2000;26:535–541.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Girish S. Munavalli
    • 1
  • Robert A. Weiss
    • 1
    • 2
  1. 1.Department of DermatologyJohns Hopkins University School of MedicineCharlotteUSA
  2. 2.Maryland Laser, Skin, and Vein InstituteHunt ValleyUSA

Personalised recommendations